Wuhan YZY Biopharma Co., Ltd. (HKG:2496)
Hong Kong · Delayed Price · Currency is HKD 4.000
-0.200 (-4.76%)
Jun 16, 2026, 2:53 PM HKT
Wuhan YZY Biopharma Revenue
In the year 2025, Wuhan YZY Biopharma had annual revenue of 66.86M CNY, down -37.99%. Wuhan YZY Biopharma had revenue of 22.49M in the half year ending December 31, 2025.
Revenue
66.86M CNY
Revenue Growth
-37.99%
P/S Ratio
10.42
Revenue / Employee
630.74K CNY
Employees
106
Market Cap
775.40M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.86M | -40.95M | -37.99% |
| Dec 31, 2024 | 107.81M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.28M | -9.89M | -81.28% |
| Dec 31, 2021 | 12.16M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3D Medicines | 396.26M |
| Cutia Therapeutics | 374.07M |
| JW (Cayman) Therapeutics Co. | 315.65M |
| CANbridge Pharmaceuticals | 55.62M |
| Shanghai Bio-heart Biological Technology | 50.00M |
| Brii Biosciences | 39.56M |
| Beijing Biostar Pharmaceuticals | 37.13M |
| Transcenta Holding | 8.27M |